FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893821657> ?p ?o ?g. }

• W2893821657 abstract "Background: Primary mediastinal B-cell lymphoma (PMBCL) is a unique and uncommon form of aggressive NHL that is potentially curable with combination chemotherapy and radiation therapy. A phase II study from the National Cancer Institute (NCI) demonstrated the effectiveness of a chemotherapy alone approach using the dose-adjusted DA-R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) regimen in the treatment of PMBCL. Given the excellent outcomes seen in this study, many hematologists adopted this regimen without consolidative radiation therapy as a front-line option for PMBCL. Aim: In our case series, we evaluate the outcomes by frontline regimen DA-R-EPOCH for the treatment of PMBCL as well as the treatment-related complications. Methods: We reported a cohort of 3 primary mediastinal large B-cell lymphoma (PMLBL) patients who had completed 8 cycles of DA-R-EPOCH by February 2018 in Hospital Melaka, Malaysia. Results: These 3 PMBCL patients were diagnosed in 2017 and all had bulky disease (>10 cm). DA-R-EPOCH treatment with an escalation dose of level 3, representing a 144% of the starting dose, were given and 40 mg of doxorubicin per square meter of body surface area were received for at least 1 cycle. Cumulative doses of anthracycline were range from 416 to 424 mg per square meter; which falls between the range in other reported studies. The 3 patients in our cohort were able to achieve partial response (PR) at the end of treatment. The average of mediastinal residual disease size was 7.13 cm. All the patients had been scheduled for radiotherapy consolidation. Hospitalization due to treatment-related complications was reported for 2 patients. One of the patients admitted to ICU due to infected chemoport. Another patient reported acquired Varicella zoster virus during the chemotherapy. He also had sinus tachycardia probably related to anthracycline with prolonged QTC and was able to be controlled by tablet carvedilol during treatment. Toxicity was assessed during administration of all the cycles of DA-R-EPOCH. Absolute neutrophil counts of less than 500 cells per cubic milliliter occurred in 30% of the cycles compared with the reported 50% in other study. The use of neutrophil-based dose adjustment maximized the delivered dose and limited the incidence of febrile neutropenia to 26% of the total cycles. Conclusion: PMBCL is a potential curable disease with combination of chemotherapy. There is no established standard treatment of PMBCL although R-CHOP chemotherapy has become a de facto standard. In fact, DA-R-EPOCH are getting more popular among treating hematologists. Our results indicated that PMBCL patients on DA-R-EPOCH regimen had a partial response and may not necessary obviate the need for radiotherapy. This is a preliminary result as 4 more patients are ongoing DA-R-EPOCH treatment." @default.
• W2893821657 created "2018-10-05" @default.
• W2893821657 creator A5001317565 @default.
• W2893821657 creator A5021803182 @default.
• W2893821657 creator A5067699456 @default.
• W2893821657 date "2018-10-01" @default.
• W2893821657 modified "2023-10-14" @default.
• W2893821657 title "Clinical Outcome of Dose-Adjusted R-Epoch in Frontline Therapy of Primary Mediastinal B-Cell Lymphoma in Hospital Melaka" @default.
• W2893821657 doi "https://doi.org/10.1200/jgo.18.87800" @default.
• W2893821657 hasPublicationYear "2018" @default.
• W2893821657 type Work @default.
• W2893821657 sameAs 2893821657 @default.
• W2893821657 citedByCount "1" @default.
• W2893821657 countsByYear W28938216572019 @default.
• W2893821657 crossrefType "journal-article" @default.
• W2893821657 hasAuthorship W2893821657A5001317565 @default.
• W2893821657 hasAuthorship W2893821657A5021803182 @default.
• W2893821657 hasAuthorship W2893821657A5067699456 @default.
• W2893821657 hasBestOaLocation W28938216571 @default.
• W2893821657 hasConcept C121332964 @default.
• W2893821657 hasConcept C126322002 @default.
• W2893821657 hasConcept C1276947 @default.
• W2893821657 hasConcept C141071460 @default.
• W2893821657 hasConcept C143998085 @default.
• W2893821657 hasConcept C150846664 @default.
• W2893821657 hasConcept C2776694085 @default.
• W2893821657 hasConcept C2776755627 @default.
• W2893821657 hasConcept C2778119113 @default.
• W2893821657 hasConcept C2779338263 @default.
• W2893821657 hasConcept C2779429289 @default.
• W2893821657 hasConcept C2780317896 @default.
• W2893821657 hasConcept C2780653079 @default.
• W2893821657 hasConcept C2781413609 @default.
• W2893821657 hasConcept C509974204 @default.
• W2893821657 hasConcept C71924100 @default.
• W2893821657 hasConceptScore W2893821657C121332964 @default.
• W2893821657 hasConceptScore W2893821657C126322002 @default.
• W2893821657 hasConceptScore W2893821657C1276947 @default.
• W2893821657 hasConceptScore W2893821657C141071460 @default.
• W2893821657 hasConceptScore W2893821657C143998085 @default.
• W2893821657 hasConceptScore W2893821657C150846664 @default.
• W2893821657 hasConceptScore W2893821657C2776694085 @default.
• W2893821657 hasConceptScore W2893821657C2776755627 @default.
• W2893821657 hasConceptScore W2893821657C2778119113 @default.
• W2893821657 hasConceptScore W2893821657C2779338263 @default.
• W2893821657 hasConceptScore W2893821657C2779429289 @default.
• W2893821657 hasConceptScore W2893821657C2780317896 @default.
• W2893821657 hasConceptScore W2893821657C2780653079 @default.
• W2893821657 hasConceptScore W2893821657C2781413609 @default.
• W2893821657 hasConceptScore W2893821657C509974204 @default.
• W2893821657 hasConceptScore W2893821657C71924100 @default.
• W2893821657 hasLocation W28938216571 @default.
• W2893821657 hasOpenAccess W2893821657 @default.
• W2893821657 hasPrimaryLocation W28938216571 @default.
• W2893821657 hasRelatedWork W1983877865 @default.
• W2893821657 hasRelatedWork W1983879800 @default.
• W2893821657 hasRelatedWork W1992953144 @default.
• W2893821657 hasRelatedWork W2061386133 @default.
• W2893821657 hasRelatedWork W2072655284 @default.
• W2893821657 hasRelatedWork W2100473045 @default.
• W2893821657 hasRelatedWork W2332529262 @default.
• W2893821657 hasRelatedWork W2894606073 @default.
• W2893821657 hasRelatedWork W2972351380 @default.
• W2893821657 hasRelatedWork W3198647362 @default.
• W2893821657 isParatext "false" @default.
• W2893821657 isRetracted "false" @default.
• W2893821657 magId "2893821657" @default.
• W2893821657 workType "article" @default.